No Data
Express News | Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-in Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for Er+ / Her2- Breast Cancer
Executive Reshuffles: NIO, Pfizer and Spirit Airlines in Focus
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright analyst Emily Bodnar maintains $Atossa Therapeutics(ATOS.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 31.6
HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
Express News | Atossa Therapeutics: Data Expected to Further Validate That (Z)-Endoxifen Is Safe & Highly Efficacious in Premenopausal Women Without Need for OFS
No Data